All articles tagged with #keytruda
Merck announced positive results from the Phase 3 KEYNOTE-B15 trial showing that combining KEYTRUDA (pembrolizumab) with Padcev (enfortumab vedotin) before and after surgery significantly improves survival and response rates in cisplatin-eligible muscle-invasive bladder cancer patients, with a safety profile consistent with known effects.
Eli Lilly's weight loss and diabetes drug tirzepatide has surpassed Merck's Keytruda as the world's best-selling medicine, driven by rapid sales growth since its approval in 2022, highlighting intense competition in the pharmaceutical market for obesity and diabetes treatments.
Merck's stock declined after its key products, Keytruda and Winrevair, fell short of sales estimates, despite overall revenue beating expectations. The company is preparing for biosimilar competition for Keytruda starting in 2028 and has made significant acquisitions to offset potential revenue declines. Merck has also updated its full-year outlook, expecting slight increases in sales and earnings for 2025.
Merck's Q3 earnings surpassed estimates driven by strong Keytruda sales, reaching over $8 billion, while adjusting its full-year profit outlook downward due to lower tariff costs and challenges in China sales of Gardasil. The company plans to cut costs and offset revenue losses from upcoming patent expirations, with revenue guidance narrowed for 2023.
The FDA approved an injectable form of Merck's key cancer drug Keytruda, offering a quicker, less invasive alternative to infusions, though Merck's stock declined despite the news. The new formulation aims to maintain sales as biosimilars enter the market and is expected to be adopted by 30-40% of patients within 18-24 months, especially in early-stage cancers.
The FDA approved Merck's new subcutaneous version of Keytruda, a popular cancer drug, which offers quicker and easier administration but is likely to maintain high prices and slow the adoption of cheaper alternatives, raising concerns about increased healthcare costs.
Merck received positive EU CHMP opinions for its cancer drug KEYTRUDA, including approval for subcutaneous administration and a new indication for earlier-stage head and neck cancer, potentially expanding treatment options in Europe.
Summit Therapeutics' lung cancer drug ivonescimab showed promising overall survival and progression-free survival results in a Phase 3 trial, but regional differences, especially between Western and Chinese patients, have raised concerns about its competitive potential against Merck's Keytruda, leading to a decline in the company's stock.
Merck reported better-than-expected Q2 earnings but its stock fell due to concerns over sales declines, patent expirations, and regulatory challenges, alongside plans for significant cost-cutting and strategic investments, including acquisitions and pipeline development.
The FDA has approved Merck's KEYTRUDA (pembrolizumab) for perioperative treatment of resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1, based on trial data showing a 30% reduction in event-free survival events, potentially shifting treatment standards for this cancer type.
Jeff Cook, diagnosed with stage four lung cancer in 2019, became cancer-free after two years of treatment with the immunotherapy drug pembrolizumab (Keytruda), highlighting the potential of new cancer treatments to significantly improve survival rates.
A Phase 3 study shows that combining Gilead's Trodelvy with Merck's Keytruda significantly reduces tumor progression risk in women with aggressive triple-negative breast cancer, potentially leading to new treatment options.
Merck is highlighted as a smart dividend stock investment due to its strategic portfolio management and consistent dividend growth. Despite the crowded pharmaceutical market, Merck has successfully maintained and grown its dividend for 14 consecutive years, largely due to its ability to acquire and develop promising drugs like Keytruda. The company's proactive approach in securing future top-selling drugs ensures continued financial stability and growth, making it an attractive option for investors seeking reliable income-producing stocks.
Merck has announced a $3.3 billion licensing deal with China's LaNova Medicines for a cancer drug, LM-299, as a strategic move against Summit Therapeutics' ivonescimab, which recently outperformed Merck's Keytruda in a lung cancer study. The deal includes a $588 million upfront payment and up to $2.7 billion in milestone payments. Both LaNova's and Summit's drugs target PD-1 and VEGF proteins, potentially offering a competitive edge over Keytruda, which only targets PD-1. This move is seen as Merck's insurance policy to maintain its market share in cancer treatments.
Two immunotherapy drugs, Keytruda and Jemperli, have shown remarkable efficacy in treating colon cancers, with Keytruda eliminating tumors in 59% of patients and Jemperli achieving a 100% success rate in a specific colorectal cancer subtype. These findings, presented at the ASCO annual meeting, suggest these drugs could significantly reduce the need for surgery and chemotherapy, although further research and larger trials are needed.